Rapid assessment of toxicity of chlorinated aqueous solution by dissolved oxygen depletion and optical density bioassays

Background: Chlorination of wastewater effluent with high levels of residual organic matter has been suspected to the production of toxic and hazardous disinfection by-products (DBPs) including trihalomethane (THM) compounds. Methods: In this study, two rapid techniques including dissolved oxygen depletion (DOD) and optical density (OD) bioassays were used to evaluate the chloroform toxicity of aqueous solution. The activated sludge was collected from aeration tank of a full-scale municipal wastewater treatment plant and used as a biological inoculum. In order to achieve an active and stabilized mixed culture of bacteria, the test cultures were transferred to a fresh nutrient broth culture media every day. The influence of chloroform on DOD and OD bioassays was examined at chloroform initial concentrations of 10-1000 μg/L. Results: It was revealed that the application of chloroform at concentrations of 100 and 1000 μg/L showed moderate and extreme toxicity, respectively, and reduced bacterial activity. The estimated chemical concentration with 50% inhibition of bacterial activity for DOD and OD bioassays was 457 and 961 μg/L, respectively. Conclusion: According to the results, the wastewater effluent should use bioassays in order to evaluate the effects of DBPs where the wastewater effluent is disinfected by chlorine compounds. Keywords: Trihalomethanes, Chloroform, Disinfection, Wastewater, Biological assay, Oxygen, Inhibitio

Proposal of upgrading Isfahan north wastewater treatment plant: An adsorption/bio-oxidation process with emphasis on excess sludge reduction and nutrient removal

There is a rising challenge in managing the activated sludge process due to excess sludge disposal from the wastewater treatment plant and inadequate effluent quality due to the stricter standard of effluent quality. Hence, the incorporation of oxic-settling-anoxic process and ultrasonic waves in the return sludge line was proposed to assess the excess sludge reduction and nutrient removal in the adsorption/bio-oxidation activated sludge process as a proposal upgrading. The results indicated that sludge production from adsorption/bio-oxidation process could be reduced using oxic-settling-anoxic and ultrasonic by 50% at each studied mixed liquor suspended solids level. Compared to the adsorption/bio-oxidation process, the total and soluble chemical oxygen demand removal efficiencies in adsorption/bio-oxidation process with oxic-settling-anoxic and ultrasonic slightly decreased suggesting a lysis phenomenon. During the operation of adsorption/bio-oxidation process with oxic-settling-anoxic and ultrasonic, the total Kjeldahl nitrogen removal efficiency improved in A and B stages, with 38.3 ± 8.1% and 83.1 ± 6.5% versus 36.8 ± 14.5% and 75.1 ± 7.3%, respectively. According to the stoichiometric calculations, in B stage of adsorption/bio-oxidation process with oxic-settling-anoxic and ultrasonic, the soluble available ultimate biochemical oxygen demand and net NO3 produced for denitrification were 69.5 and 43.8 mg/L, respectively. Overall, the experimental data revealed that the adsorption/bio-oxidation process with oxic-settling-anoxic and ultrasonic produced lower excess biological sludge and better total Kjeldahl nitrogen removal efficiency compared to the adsorption/bio-oxidation system alone

Combination of hydrodynamic cavitation with oxidants for efficient treatment of synthetic and real textile wastewater

In this study, the degradation of direct red 89 (DR89) dye from synthetic wastewater was assessed by lab-scaled hydrodynamic cavitation (HC) combined with different oxidants such as periodate (PI), persulfate (PS), and oxalic acid (OA). The degradation tests were carried out by combining the three oxidants in the absence of HC, and using HC with only one of the oxidants (HC/OA, HC/PS, and HC/PI) or with all combined (HC/PS/OA/PI). In all processes, the degradation constants followed first-order reaction kinetics, being the highest one that of the HC/PS/OA/PI process, equal to 2.01 × 10− 1 min− 1 . The degradation of DR89 was affected by pH, initial dye concentration, and reaction time. The degradation efficiency increased when pH decreased obtaining the best results at pH 3.0 due to favorable conditions for the generation and persistence of radical species. The degradation of the dye improved with increasing dose of OA, PS and PI. The best results were achieved using dosages of OA, PS, and PI of 100.0, 125.0, and 150.0 mg L− 1 , respectively. The quenching experiments revealed the presence of • OH, SO4 •− , IO3 • , O2 •– , and 1 O2 in the HC/PS/OA/PI process, while • OH, SO4 •− and IO3 • were the dominant responsible radicals. The rate constants of the individual processes were used to calculate the value of the synergetic coefficient of HC/PS/OA/PI process. At the optimum conditions, the calculated synergetic coefficient was 15.39. The effectiveness of the HC/PS/OA/PI process in the removal of color and COD from real textile wastewater was also investigated and exhibited the 96.23 ± 1.92 % and 93.84 ± 0.94 % reduction of color and COD after 70 min reaction time, respectively. The results showed that the combined process can be a useful technology for the treatment of textile wastewateThe authors thank the Isfahan University of Medical Sciences of Iran (Project No. 198124 and Ethics code: IR.MUI.RESEARCH. REC.1398.500) for financial support of this wor

Magnetized Activated Carbon Synthesized from Pomegranate Husk for Persulfate Activation and Degradation of 4-Chlorophenol from Wastewater

The compound 4-chlorophenol (4-CP) is known to be a highly toxic compound having harmful effects on human health and the environment. To date, the removal of 4-CP by advanced oxidation processes (AOPs) has attracted tremendous attentions. The persulfate-based AOPs show higher oxidation, better selectivity, wider pH range, and no secondary pollution compared to the traditional Fenton-based AOPs. Carbon materials with low cost and chemical stability are useful for the activation of persulfate (PS) to produce reactive species. Herein, we magnetized activated carbon synthesized from pomegranate husk (MPHAC). By using 4-CP as a model organic pollutant, tests of the activation of PS via MPHAC for the removal of 4-CP were performed. Batch processes were carried out to study the influence of different parameters (initial solution pH, catalyst dose, PS dose, and initial 4-CP concentration) on the adsorption of 4-CP on PHAC with ferric oxide (Fe3O4-PHAC). The results show that under the obtained optimal conditions (MPHAC dose: 1250 mg/L, PS dose: 350 mg/L, solution pH 5, an initial 4-CP concentration of 100 mg/L, and a contact time of 60 min), a 4-CP removal factor of 99.5% was reached by the developed MPHAC/PS system. In addition, it was found that reusing MPHAC in five successive cycles is feasible because the catalyst in the last cycle kept exhibiting a high potential for 4-CP absorption, indicating the economically viable procedure. Therefore, this study provides a comprehensive understanding on the degradation of 4-CP by the magnetized activated carbon persulfate system

Electron flow of biological H2 production by sludge under simple thermal treatment: Kinetic study

Mixed culture sludge has been widely used as a microbial consortium for biohydrogen production. Simple thermal treatment of sludge is usually required in order to eliminate any H2-consuming bacteria that would reduce H2 production. In this study, thermal treatment of sludge was carried out at various temperatures. Electron flow model was then applied in order to assess community structure in the sludge upon thermal treatment for biohydrogen production. Results show that the dominant electron sink was acetate (150–217 eˉ meq/mol glucose). The electron equivalent (eˉ eq) balances were within 0.8–18% for all experiments. Treatment at 100 °C attained the highest H2 yield of 3.44 mol H2/mol glucose from the stoichiometric reaction. As the treatment temperature increased from 80 to 100 °C, the computed acetyl-CoA and reduced form of ferredoxin (Fdred) concentrations increased from 13.01 to 17.34 eˉ eq (1.63–2.17 mol) and 1.34 to 4.18 eˉ eq (0.67–2.09 mol), respectively. The NADH2 balance error varied from 3 to 10% and the term eˉ(Fd↔NADH2) (m) in the NADH2 balance was NADH2 consumption (m = −1). The H2 production was mainly via the Fd:hydrogenase system and this is supported with a good NADH2 balance. Using the modified Gompertz model, the highest maximum H2 production potential was 1194 mL whereas the maximum rate of H2 production was 357 mL/h recorded at 100 °C of treatment

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Funding: F Carvalho and E Fernandes acknowledge support from Fundação para a Ciência e a Tecnologia, I.P. (FCT), in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy i4HB; FCT/MCTES through the project UIDB/50006/2020. J Conde acknowledges the European Research Council Starting Grant (ERC-StG-2019-848325). V M Costa acknowledges the grant SFRH/BHD/110001/2015, received by Portuguese national funds through Fundação para a Ciência e Tecnologia (FCT), IP, under the Norma Transitória DL57/2016/CP1334/CT0006.proofepub_ahead_of_prin

The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019

Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026

Background The COVID-19 pandemic highlighted gaps in health surveillance systems, disease prevention, and treatment globally. Among the many factors that might have led to these gaps is the issue of the financing of national health systems, especially in low-income and middle-income countries (LMICs), as well as a robust global system for pandemic preparedness. We aimed to provide a comparative assessment of global health spending at the onset of the pandemic; characterise the amount of development assistance for pandemic preparedness and response disbursed in the first 2 years of the COVID-19 pandemic; and examine expectations for future health spending and put into context the expected need for investment in pandemic preparedness. Methods In this analysis of global health spending between 1990 and 2021, and prediction from 2021 to 2026, we estimated four sources of health spending: development assistance for health (DAH), government spending, out-of-pocket spending, and prepaid private spending across 204 countries and territories. We used the Organisation for Economic Co-operation and Development (OECD)'s Creditor Reporting System (CRS) and the WHO Global Health Expenditure Database (GHED) to estimate spending. We estimated development assistance for general health, COVID-19 response, and pandemic preparedness and response using a keyword search. Health spending estimates were combined with estimates of resources needed for pandemic prevention and preparedness to analyse future health spending patterns, relative to need. Findings In 2019, at the onset of the COVID-19 pandemic, US$9·2 trillion (95$7·3 trillion (95% UI 7·2–7·4) in 2019; 293·7 times the $24·8 billion (95$43·1 billion in development assistance was provided to maintain or improve health. The pandemic led to an unprecedented increase in development assistance targeted towards health; in 2020 and 2021, $1·8 billion in DAH contributions was provided towards pandemic preparedness in LMICs, and$37·8 billion was provided for the health-related COVID-19 response. Although the support for pandemic preparedness is 12·2% of the recommended target by the High-Level Independent Panel (HLIP), the support provided for the health-related COVID-19 response is 252·2% of the recommended target. Additionally, projected spending estimates suggest that between 2022 and 2026, governments in 17 (95% UI 11–21) of the 137 LMICs will observe an increase in national government health spending equivalent to an addition of 1% of GDP, as recommended by the HLIP. Interpretation There was an unprecedented scale-up in DAH in 2020 and 2021. We have a unique opportunity at this time to sustain funding for crucial global health functions, including pandemic preparedness. However, historical patterns of underfunding of pandemic preparedness suggest that deliberate effort must be made to ensure funding is maintained

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation